Mass Torts

July 29, 2026

Bard PowerPort Lawsuit

Bard PowerPort lawsuits allege that defects in implanted port catheters can cause fractures, migration, blood clots, infections, embolisms, and other serious complications. Thousands of product liability lawsuits are now pending against Bard and its parent company, Becton Dickinson, in a federal multidistrict litigation in Arizona.

The first bellwether trial ended with a partial defense verdict and a deadlocked jury on the central design defect claim. The next trial, Divelbliss v. C.R. Bard, is scheduled to begin on August 18, 2026. It involves an alleged fracture of a silicone Groshong catheter. Five bellwether trials are now expected to run through February 2027. Our lawyers remain bullish on well-documented fracture, migration, and embolization cases. Infection-only claims may face harder causation arguments and could receive lower settlement offers if Bard eventually proposes a global resolution.

This page provides the latest Bard PowerPort lawsuit updates, projected settlement amounts, and information about who may qualify to file a claim. No global settlement has been announced, and all payout estimates remain speculative.

July 29, 2026

Spinal Cord Stimulator Lawsuit

by Ronald V. Miller, Jr.

A spinal cord stimulator is an implantable medical device used to manage chronic pain, most often involving the back or spine. These systems are marketed as a way to reduce pain by interrupting nerve signals before they reach the brain. But for a growing number of patients, the device fails to help. It introduces new and sometimes permanent problems, including electrical shocks, burning pain, infections, lead migration, hardware failure, and repeat surgeries to reposition or remove equipment that was supposed to improve quality of life.

This page explains spinal cord stimulator lawsuits and why they are being filed nationwide. It focuses on what patients are alleging, how these devices have failed in real-world use, and why many of these cases go beyond ordinary medical malpractice claims. The most serious lawsuits do not center on a single surgical mistake. They examine how modern spinal cord stimulators were designed, tested, and approved, and whether patients were ever adequately warned about the risks that now recur repeatedly in medical records and FDA reports.

Many people arrive here with a practical question in mind: what do spinal cord stimulator settlement amounts look like, and how does compensation get calculated when a device causes lasting harm? That question cannot be answered in isolation. Settlement amounts and payouts are driven by the full medical timeline, including the costs of repeat surgeries, explantation, and permanent loss of function, as well as the downstream consequences when a pain-management device leaves someone worse off than before it was implanted.

July 29, 2026

Depo Provera Lawsuit Settlements

by Ronald V. Miller, Jr.

This page is for women considering filing a Depo-Provera lawsuit. Our lawyers provide the latest updates, explain the litigation and settlement process, and offer our assessment of potential Depo-Provera settlement amounts.

Scientific research has found a strong association between prolonged use of injectable medroxyprogesterone acetate, the active drug in Depo-Provera, and intracranial meningioma. Women who received Depo-Provera injections and were later diagnosed with a meningioma are filing lawsuits alleging that Pfizer and related companies failed to provide an adequate warning.

Our attorneys are reviewing these cases nationwide. If you believe you may have a Depo-Provera claim, call us at 800-553-8082 or contact us online.

July 29, 2026

Ozempic Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are investigating Ozempic lawsuits for patients with NAION, gastroparesis or gastrointestinal conditions, including bowel obstruction or cyclic vomiting syndrome.

Ozempic is the popular brand name for semaglutide, a prescription drug approved for the treatment of type 2 diabetes. As we all know, Ozempic is also commonly used as a weight management drug. Recent scientific studies have shown that taking Ozempic, particularly at higher doses, can cause gastroparesis.

July 29, 2026

Suboxone Tooth Decay Lawsuit Update

by Ronald V. Miller, Jr.

This page explains the Suboxone tooth decay lawsuits, the dental injuries linked to Suboxone film, and where the federal MDL stands in 2026.

The core claim in the Suboxone litigation is straightforward: plaintiffs allege that Indivior and related defendants knew, or should have known, that Suboxone film could cause severe dental damage, including tooth decay, enamel erosion, broken teeth, tooth loss, and expensive dental reconstruction. Plaintiffs contend the companies failed to warn patients and prescribing doctors until the FDA forced a dental warning in 2022.

Our firm is not accepting new Suboxone cases in 2026. This page is provided for litigation updates and general information for victims and their families

July 28, 2026

NEC Baby Formula Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are handling Similac and Enfamil infant formula lawsuits for families whose premature babies suffered or died from necrotizing enterocolitis (NEC) after taking one of these formulas. Our law firm is reviewing NEC lawsuits in all 50 states.

Medical research links cow milk-based infant formulas such as Similac and Enfamil to a dangerous neonatal medical condition known as necrotizing enterocolitis. These newborn NEC formula lawsuits make many allegations. But at their core, they allege that the makers of these formulas knew of the risk of NEC and did nothing to warn families and give them a choice.

If your premature baby was diagnosed with NEC after being given Similac or Enfamil formula, you may be able to participate in a class action lawsuit against the formula companies and receive financial compensation for the harm that was done to your child.

July 28, 2026

Talc Powder Ovarian Cancer Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are handling baby powder lawsuits in all 50 states in 2026. The talcum powder lawsuits against Johnson & Johnson have been ongoing for years. The lawsuits allege that prolonged use of talcum powder (or “talc”), the active ingredient in products such as Baby Powder and Shower to Shower, can cause ovarian cancer in some women.

This page provides an update on J&J talc powder litigation and discusses the settlement amounts in ovarian cancer lawsuits for victims.

Has the deadline passed for you to file a talcum powder lawsuit? Many who assume the statute of limitations has passed to sue Johnson & Johnson may be wrong. Call us today at 800-553-8082 or get a free and quick case review online.

July 27, 2026

Hair Relaxer Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are reviewing hair relaxer cancer lawsuits for women throughout the United States. These claims involve women who used chemical hair relaxers or hair straighteners for years and were later diagnosed with uterine cancer, including endometrial cancer, ovarian cancer, or serious uterine fibroids that led to a hysterectomy.

The federal hair relaxer litigation now includes nearly 12,000 plaintiffs. The cases are moving through expert discovery and bellwether preparation in the Northern District of Illinois. No hair relaxer settlement has been announced, and no plaintiff has received a settlement payout through the federal MDL. The latest hair relaxer lawsuit update is that Judge Mary Rowland has lifted a discovery stay for a group of defendants after concluding that settlement discussions had not produced enough progress to justify keeping those cases frozen.

The strongest cases generally involve frequent, long term use followed by uterine or ovarian cancer, a clear product history, and substantial treatment or reproductive injury.

July 27, 2026

Paragard IUD Lawsuit Settlement Amounts

by Ronald V. Miller, Jr.

Our lawyers are handling Paragard IUD lawsuits for women throughout the United States. These cases allege that the copper IUD can fracture during removal, leaving one or both plastic arms inside the uterus and sometimes forcing the patient to undergo another procedure or surgery.

The federal litigation now includes more than 4,000 filed cases. The first bellwether trial ended in a defense verdict in February 2026. That was a real loss for plaintiffs, and it changed the settlement calculus maybe a bit. But it is just one case, and all that can be turned around with a win in September 2026 when we have the next trial.

So there is no Paragard settlement program or average payout in July 2026. Our lawyers still believe these claims may eventually be resolved through a negotiated settlement, but the first defense verdict makes it harder to predict when that could happen or what defendants will be willing to pay. We discuss our estimated Paragard settlement values below.

July 23, 2026

Chlorpyrifos Lawsuits

by Ronald V. Miller, Jr.

Chlorpyrifos lawsuits allege that repeated exposure to this widely used insecticide can contribute to Parkinson’s disease. The people most likely to bring these claims are farmers, pesticide applicators, pest control workers, groundskeepers, greenhouse employees, and others who personally mixed, loaded, sprayed, or cleaned up chlorpyrifos products over months or years.

Chlorpyrifos was sold under trade names that include Dursban, Lorsban, Cobalt, Nufos, Bolton, Stallion, Pilot, Warhawk, and Hatchet. It was used on farms, golf courses, ornamental plants, and residential and commercial properties. Many workers remember the trade name but not the active ingredient. Product identification is therefore one of the first and most important parts of investigating a claim.

If you have Parkinson’s disease after years of working with pesticides, you may have wondered whether that exposure played a role. A December 2025 study gives lawyers and scientists a serious reason to investigate chlorpyrifos. Researchers associated estimated long-term residential exposure near agricultural applications with more than 2.5 times the risk of Parkinson’s disease. They also found Parkinson’s-related brain damage in mice that inhaled chlorpyrifos.